1 ed, allowing for the initiation of a Phase-2
proof of concept study.
2 sis in a double-blind sham-controlled design
proof of concept study.
3 e-blind, placebo-controlled human laboratory
proof-of-concept study.
4 ter, randomized, open-label, parallel-group,
proof-of-concept study.
5 percutaneous nephrolithotomy (PCNL) in this
proof-of-concept study.
6 d only 2 hospitals in Tanzania and is thus a
proof-of-concept study.
7 uropeptide FF analogue) were subject of this
proof-of-concept study.
8 as a potent and selective tool compound for
proof of concept studies.
9 rmacokinetics allowing for the initiation of
proof of concept studies.
10 iral therapy (HXTCs) are a powerful tool for
proof-of-concept studies.
11 routine care in non-randomised, exploratory
proof-of-concept studies.
12 mphasis on mechanistic advances and clinical
proof-of-concept studies.
13 use is an appropriate model for pre-clinical
proof-of-concept studies.
14 te highly encouraging results in preclinical
proof-of-concept studies.
15 d provides a clear path forward for clinical
proof-of-concept studies.
16 g will likely be small and closely monitored
proof-of-concept studies.
17 tentially limiting their utility for in vivo
proof-of-concept studies.
18 ) antifibrotic trial design; (2) preclinical
proof-of-concept studies; (
3) pharmacological targets, i
19 In this
proof-of-concept study,
39 patients with early RA and cl
20 In this
proof-of-concept study,
a positive PV-Haufen test was on
21 This
proof-of-concept study aimed to assess the effect of par
22 This is a
proof of concept study aiming to quantify neurovascular
23 In this
proof-of-concept study,
all patients with chronic HCV wi
24 ion limits of 99 nM were established in this
proof-of-concept study (
although significantly lower val
25 In this
proof-of-concept study,
an active-template coupling is u
26 On the basis of
proof-of-concept studies and an excellent safety profile
27 antibody discovery strategy that facilitates
proof-of-concept studies and clinical candidate antibody
28 utic targets is of enormous utility for both
proof-of-concept studies and for the development of pote
29 This oversight potentially confounds
proof-of-concept studies and increases drug development
30 ic studies; identified studies also included
proof-of-concept studies and key phase 1 through 3 trial
31 from Escherichia coli and Vibrio harveyi in
proof-of-concept studies and was then used to directly m
32 highlight the portfolio of clinical trials,
proof-of-concept studies,
and mechanistic studies planne
33 As a
proof-of-concept study,
antibodies against the emerging
34 Implications of this
proof of concept study are that fluorescent conjugates o
35 Proof-of-concept studies are being conducted that show t
36 Proof-of-concept studies are needed to determine: 1) the
37 cy and pharmacological properties useful for
proof-of-concept studies are not available.
38 ces in the field of ocular gene therapy, and
proof-of-concept studies are under way to evaluate the s
39 n human SSc, and conduct of biomarker-driven
proof-of-concept studies as a bridge between animal stud
40 d, double-blind, placebo-controlled, phase 2
proof-of-concept study at 35 centres in the USA.
41 In this
proof-of-concept study azithromycin treatment during RSV
42 n has been delayed by reluctance to initiate
proof-of-concept studies,
but after recent trials, prote
43 New therapeutic options with positive
proof-of-concept studies,
but with limited clinical expe
44 this study was that part 2 was designed as a
proof-of-concept study by contrast with part 1.
45 In this
proof of concept study,
chemical threat agent (CTA) samp
46 In this pilot
proof of concept study,
chronic protein therapy with SC
47 ropin (hCG) was used as a model protein in a
proof-of-concept study combining water-soluble dried blo
48 a randomized double-blind placebo-controlled
proof of concept study comparing 8 weeks of SC BNP (10 m
49 However, a series of relatively small
proof-of-concept studies conducted over the last 15 year
50 This
proof of concept study confirmed that algal-bacterial ph
51 This pilot,
proof-of-concept study consisted of a randomised, double
52 This
proof of concept study could greatly impact the accessib
53 mon light chain and the hinge disulfides for
proof-of-concept studies coupled with the identification
54 Proof-of-concept studies demonstrate successful culture
55 In summary, the
proof-of-concept study demonstrated that next-generation
56 This
proof of concept study demonstrates that bacterial flora
57 Our
proof of concept study demonstrates that MALDI MSI could
58 This
proof of concept study demonstrates that pericardial res
59 This
proof of concept study demonstrates the feasibility of a
60 This "
proof of concept" study demonstrates that human exposure
61 This
proof-of-concept study demonstrates a modular approach t
62 This human
proof-of-concept study demonstrates systemic administrat
63 This
proof-of-concept study demonstrates that gene therapy de
64 This
proof-of-concept study demonstrates that immunization wi
65 This
proof-of-concept study demonstrates that it is possible
66 This mechanistic human
proof-of-concept study demonstrates that micropore lifet
67 This
proof-of-concept study demonstrates that modulating TR2/
68 This
proof-of-concept study demonstrates that neural interfac
69 This
proof-of-concept study demonstrates that no longer routi
70 This
proof-of-concept study demonstrates that the proposed sy
71 This
proof-of-concept study demonstrates that the tissue orig
72 This
proof-of-concept study demonstrates the feasibility of a
73 This
proof-of-concept study demonstrates the possibility of d
74 This
proof-of-concept study demonstrates the potential of MRI
75 This
proof-of-concept study demonstrates the potential of the
76 This
proof-of-concept study demonstrates the quantitative ima
77 This
proof-of-concept study demonstrates the value of Raman s
78 Recent
proof of concept studies demonstrating the capacity to e
79 This work represents a
proof-of-concept study demonstrating the utility of enzy
80 We present a
proof of concept study designed to support the clinical
81 Cure experiments are
proof-of-concept studies designed to evaluate novel para
82 In a
proof-of-concept study,
eight patients with depression l
83 This multicenter, open-label,
proof-of-concept study evaluated the anti-IL12/23 monocl
84 This first-in-human
proof-of-concept study evaluated the clinical and biolog
85 This experimental approach is feasible for
proof-of-concept studies evaluating new treatments for a
86 This
proof-of-concept study examined safety and efficacy of s
87 This
proof of concept study explored using a novel digital-me
88 This
proof-of-concept study explored the feasibility of using
89 These findings validate a
proof of concept study exposure of extant tumor lines to
90 This
proof-of-concept study focused on hip fractures, but use
91 tudy provides a potential platform for early
proof of concept studies for NTHi vaccines, as well as a
92 hy human subjects prior to the initiation of
proof of concept studies for the treatment of mood disor
93 These data represent a
proof of concept study for basic decoding of speech imag
94 We focus on
proof-of-concept studies for a direct microarray-based a
95 ative, ADL5859 (4), is currently in phase II
proof-of-concept studies for the management of pain.
96 In this manuscript, we present a
proof-of-concept study for targeted relative protein qua
97 guanylate cyclase-C, has shown benefit in a
proof-of-concept study for the treatment of patients wit
98 g further studies directed toward a clinical
proof-of-concept study for this class of ocular hypotens
99 Proof-of-concept studies from a growing number of invest
100 This
proof-of-concept study has led to an ongoing systemic cl
101 discovery of gammadelta T cells >30 y ago, a
proof-of-concept study has not been done to prove the pr
102 As a significant number of
proof-of-concept studies have been published, it is impo
103 ts that potentially influence the host, many
proof-of-concept studies have demonstrated causative rol
104 Recently,
proof-of-concept studies have demonstrated genotype-phen
105 Indeed, preclinical
proof-of-concept studies have demonstrated that both G p
106 Proof-of-concept studies have recently been reported, us
107 Various
proof-of-concept studies have shown the potential of bio
108 In this
proof-of-concept study,
HeartLander demonstrated semiaut
109 In this
proof-of-concept study,
HMWCs were observed in 31 of 77
110 Overall, this
proof-of-concept study illustrates an efficient, general
111 Thus, these compounds are useful for
proof of concept studies in a variety of models where EP
112 Proof of concept studies in healthy young male human sub
113 andomized, double-blind, placebo-controlled,
proof-of-concept studies in 2 clinically challenging ADH
114 bility, thus making it an effective tool for
proof-of-concept studies in a clinical setting.
115 es face daunting challenges in the design of
proof-of-concept studies in animal models.
116 Based on first
proof-of-concept studies in bacteria a decade ago, synth
117 er preclinical evaluation as a candidate for
proof-of-concept studies in humans.
118 may be a useful clinical trial end point for
proof-of-concept studies in patients with DR.
119 esting a practical translational pathway for
proof-of-concept studies in people with spinal cord inju
120 Proof-of-concept studies in the 1980s demonstrated that
121 Based on
proof-of-concept studies in the Plasmodium yoelii murine
122 ed, three-way, incomplete block, cross-over,
proof-of-concept study in 71 patients with AR, evaluated
123 In a
proof-of-concept study in a muscle-specific ring finger
124 We did a
proof-of-concept study in four volunteers infected with
125 Here, we performed a
proof-of-concept study in order to determine the potenti
126 a 24-week randomized, double-blind, clinical
proof-of-concept study in overweight/obese subjects, coa
127 Preclinical studies as well as a
proof-of-concept study in type 1 diabetic patients and h
128 t this hypothesis clinically, we developed a
proof-of-concept study,
in which patients with EGFR-muta
129 Additionally, a preliminary
proof-of-concept study indicated an amide I band shift b
130 Conclusion This
proof-of-concept study indicates that TA of nonenhanced
131 een human and mouse diseases will complicate
proof-of-concept studies intended to advance treatment i
132 Some of these compounds have now moved from
proof-of-concept studies into clinical trials, with pros
133 The second
proof-of-concept study involved the fabrication of a 96-
134 This
proof-of-concept study involves plasmonic characterizati
135 A
proof of concept study involving the online coupling of
136 Surprisingly, techniques used in
proof-of-concept studies involving abnormally fertilized
137 andomized, double-blind, placebo-controlled,
proof-of-concept study involving 111 infants less than 1
138 A "
proof of concept" study is reported, which demonstrates
139 e poor predictiveness of today's preclinical
proof-of-concept studies is related not to limitations o
140 The first
proof-of-concept study is carried out with 5- and 7-chan
141 A
proof-of-concept study is conducted on the detection of
142 uencing to predict rejection events, as this
proof-of-concept study is limited to a small number of p
143 This initial
proof-of-concept study is the first application of DREAD
144 This
proof-of-concept study is the first in which the culture
145 This
proof-of-concept study is the first to identify a mechan
146 In this
proof-of-concept study,
it appears feasible to perform a
147 Despite promising results in several
proof-of-concept studies,
its translation to the clinica
148 Collectively, this
proof-of-concept study links urine peptidomics to molecu
149 This
proof-of-concept study may aid in the diagnosis of histo
150 of the peripheral nervous system in MS, this
proof-of-concept study may offer new insights into the p
151 Proof of concept studies of tissue phantoms yielded a me
152 This work presents a
proof of concept study of this idea.
153 In our recent article, we elaborate our
proof-of-concept studies of a mouse/human chimeric IgE a
154 ctrochemical immunosensor for human IL-6 and
proof-of-concept studies of IL-6 detection in HNSCC cell
155 get engagement and assist dose selection for
proof-of-concept studies of PAM compounds.
156 en employed in the literature as a model for
proof-of-concept studies of perspective biosensing appli
157 homologs in the mouse has precluded in vivo
proof-of-concept studies of specific therapies targeting
158 cit specific immunity, setting the stage for
proof-of-concept studies of these new protein vaccines i
159 In this pilot
proof-of-concept study of DME, minocycline as primary tr
160 veral widely used datasets and apply it to a
proof-of-concept study of orthologous proteomes in an in
161 Here, by presenting a series of
proof-of-concept studies on electrically triggered funct
162 Therefore, we present a
proof-of-concept study on an analytical experimental tes
163 This
proof-of-concept study on MICA measurements by ProtoArra
164 We show a
proof-of-concept study on the amphiphysin-1 SH3 domain i
165 We performed a
proof-of-concept study on the SH2 domains of SAP and Grb
166 ccuracy and reproducibility achieved in this
proof-of-concept study opens substantive avenues for cha
167 As a
proof-of-concept study,
our microfluidic device was coup
168 ) initial short-term readouts in early phase/
proof-of-concept studies over 6 or 9 months, and (2) sec
169 In these open-label
proof-of-concept studies,
patients with ALS were enrolle
170 This
proof of concept study paves the route toward a potentia
171 The
proof-of-concept studies performed using the chimeric ph
172 The
proof-of-concept study (
POC) was an 8-week, double-blind
173 In this
proof of concept study,
pretreatment with simvastatin in
174 These
proof-of-concept studies provide a platform for the inve
175 Proof-of-concept studies provided additional evidence fo
176 This
proof of concept study provides an approach for the rati
177 This
proof-of-concept study provides a basis for developing a
178 This
proof-of-concept study provides a new direction for regu
179 This
proof-of-concept study provides a new methodology for NI
180 This
proof-of-concept study provides a platform that could be
181 This
proof-of-concept study provides a simple yet robust appr
182 This
proof-of-concept study provides clues that hepatic USPIO
183 Our novel
proof-of-concept study provides evidence that downregula
184 Our
proof-of-concept study provides time-resolved insight in
185 In this
proof-of-concept study,
Raman microscopy was used to dif
186 In this
proof-of-concept study,
Raman microspectroscopy was util
187 In a
proof-of-concept study,
rapid screening of ten samples w
188 Our
proof-of concept study results demonstrate CMLD-2 repres
189 eliable and predictive data from preclinical
proof-of-concept studies,
results that should more rapid
190 Findings: Multiple
proof-of-concept studies reveal the feasibility and effi
191 In this
proof-of-concept study,
rituximab, which is a reference
192 This
proof-of-concept study sheds light on genotype-phenotype
193 Data from our
proof-of-concept study show that SL RNA detection has hi
194 The
proof-of-concept study showed that BBD treatment of MTB-
195 This is a first
proof of concept study showing that modulating the catab
196 ility of this approach is examined through a
proof-of-concept study showing enzyme-directed particle
197 This is a robust
proof-of-concept study showing that exogenous ghrelin re
198 This
proof of concept study shows that the re-establishment o
199 This
proof-of-concept study shows that the development of bot
200 In this
proof-of-concept study,
stable isotope probing (SIP) was
201 Results of this
proof-of-concept study suggest that a larger trial, powe
202 The results of this
proof-of-concept study suggest that agents that can mimi
203 Our
proof of concept study suggests that scaffolds loaded wi
204 This
proof-of-concept study suggests a beneficial role of dop
205 This
proof-of-concept study suggests a new multivariable anal
206 This
proof-of-concept study suggests that activation of ocula
207 This successful
proof-of-concept study suggests that drugs targeting NS4
208 This novel
proof-of-concept study suggests that in severe placental
209 This
proof-of-concept study suggests that the Soul Mate could
210 This
proof-of-concept study suggests that TNF antagonism does
211 These
proof-of-concept studies support the further optimizatio
212 These
proof-of-concept studies support the use of IONPs to enh
213 review RNAi-based gene-silencing strategies,
proof-of-concept studies testing therapeutic RNAi for CN
214 adrenergic receptor as a model, we present a
proof of concept study that assessed the bias of 19 beta
215 We have recently shown in an interventional,
proof-of-concept study that leptin can restore ovulatory
216 We describe a
proof-of-concept study that uses a model system consisti
217 Here we show, in this
proof-of-concept study,
that [1-(13)C] alpha-ketoglutara
218 In this
proof of concept study,
the sensor was utilized to inves
219 In this
proof of concept study,
the surface morphology of a rabb
220 In a
proof-of-concept study,
the 3D CMs have been further exp
221 In this
proof-of-concept study,
the administration of pioglitazo
222 In a
proof-of-concept study,
the decellularized grafts are im
223 In a preclinical
proof-of-concept study,
the ex vivo and in vivo [(11)C]5
224 In this
proof-of-concept study,
the feasibility of this techniqu
225 In this
proof-of-concept study,
the use of a covalent binding pe
226 In a
proof-of-concept study,
through only external calibratio
227 pursued by the research community for these
proof-of-concept studies to achieve the goal of accelera
228 istory in this model will permit preclinical
proof-of-concept studies to be designed and such studies
229 This is the first
proof-of-concept study to apply SERS-based detection usi
230 dministered in an open-label, nonrandomized,
proof-of-concept study to attempt to prevent viral rebou
231 We did a nested, case-control,
proof-of-concept study to compare the prevalence of CHIP
232 This is the first
proof-of-concept study to demonstrate successful read-th
233 Here, we present a
proof-of-concept study to determine the feasibility of u
234 The present study is designed as a
proof-of-concept study to evaluate light/chemical harden
235 erformed a double-blind, placebo-controlled,
proof-of-concept study to evaluate the effects of OCA on
236 Here, we present a
proof-of-concept study to examine the microbial link bet
237 Here we report a
proof-of-concept study to integrate genomic prediction i
238 ctrometry has been demonstrated, via various
proof-of-concept studies,
to offer a powerful, rather un
239 tinal degenerative disorders now moving from
proof-of-concept studies toward clinical trials.
240 In this
proof-of-concept study,
treatment with tanezumab was ass
241 For
proof-of-concept studies,
two crucial redox enzymes for
242 In this small
proof-of-concept study,
two different three-drug regimen
243 tutional review board-approved, prospective,
proof-of-concept study,
unaffected and affected gut segm
244 Proof of concept studies using a rat orthotopic lung tra
245 Proof-of-concept studies using a murine model of BOS not
246 The role of SOCS1 was inferred by
proof-of-concept studies using overexpression with repor
247 An in vivo
proof-of-concept study using a DOTA-folate conjugate dem
248 In this
proof-of-concept study,
using stem cells derived from sk
249 The results of this
proof-of-concept study warranted further research invest
250 A human clinical
proof-of-concept study was completed in eight FA patient
251 This
proof-of-concept study was conducted to determine whethe
252 A
proof-of-concept study was conducted to evaluate an alte
253 A
proof-of-concept study was conducted using T2 bacterioph
254 This
proof-of-concept study was designed to determine if func
255 This
proof-of-concept study was designed to investigate the s
256 sed on a meta-Lasso regression model and the
proof-of-concept study was performed using a large-scale
257 Proof-of-concept study was performed with caper bud extr
258 This
proof-of-concept study was then extended to include anal
259 The aim of this
proof-of-concept study was to evaluate a novel CXCR4-tar
260 The goal of this
proof-of-concept study was to produce all 4 terbium radi
261 In
proof-of-concept studies we validated 16 high-confidence
262 Here, in a first
proof-of-concept study we tested whether SD induces a de
263 In the current
proof-of-concept study we utilized TERS to identify indi
264 As a model (an example or
proof-of-concept study)
we have used a functional calciu
265 In this
proof of concept study,
we combine the advantages of an
266 In
proof-of-concept studies,
we further documented differen
267 In a
proof-of-concept study,
we aimed to assess the effect on
268 As a
proof-of-concept study,
we attempted to identify a synth
269 In a
proof-of-concept study,
we defined two groups (1) an acu
270 In this
proof-of-concept study,
we demonstrate basic feasibility
271 As a
proof-of-concept study,
we demonstrate parallel resequen
272 In a
proof-of-concept study,
we demonstrate that our device c
273 erein, taking beta-Ni(OH)2 nanosheets as the
proof-of-concept study,
we demonstrated a surface-chemis
274 In this
proof-of-concept study,
we demonstrated that (89)Zr-tras
275 In a
proof-of-concept study,
we enrolled 10 patients with lun
276 In a
proof-of-concept study,
we established CTC cultures from
277 In our
proof-of-concept study,
we evaluated the capability of t
278 rkB is internalized upon activation; in this
proof-of-concept study,
we exploited this fact to isolat
279 As a
proof-of-concept study,
we have applied matrix-assisted
280 In this
proof-of-concept study,
we implemented a molecular-barco
281 In a
proof-of-concept study,
we previously showed that colore
282 In our
proof-of-concept study,
we resolve the silicon lattice d
283 In a
proof-of-concept study,
we show that a novel vaccine app
284 Here, in a
proof-of-concept study,
we show that immunization of tra
285 uantification of NF-L in blood, and ii) in a
proof-of-concept study,
we tested our newly developed me
286 In a
proof-of-concept study,
we used a unique, homology-depen
287 Proof of concept studies were performed to detect saliva
288 Proof-of-concept studies were conducted in breast and pr
289 a transgenic mouse model of prostate cancer,
proof-of-concept studies were performed to first establi
290 The aims of this
proof-of-concept study were to determine whether an expe
291 antibody, exhibited promising activity in a
proof-of-concept study when administered in intravenous
292 hortened half-life in vivo Here we present a
proof of concept study where we identify sites to incorp
293 The aim of this study was a
proof of concept study whether these same data sets can
294 This
proof-of-concept study,
which employs a chiral pool suga
295 as considered indicative of a trend for this
proof of concept study,
while statistical significance w
296 Proof-of-concept studies with CD3xHER2 BsAb (T-cell recr
297 Proof-of-concept studies with HER2xCD3 (T-cell recruitme
298 reath sampling and analysis are challenging,
proof-of-concept studies with mass spectrometry and elec
299 The first
proof-of-concept studies with the clinically relevant ca
300 glucosidase inhibitors, as demonstrated by a
proof-of-concept study with extract of 'Pink Lady' apple